LifeSci Capital Initiates Coverage of CoLucid Pharmaceuticals

Developing a Novel Migraine Treatment that is Differentiated from Triptans; Report Available here: www.lifescicapital.com/equity-research/colucid/

NEW YORK, NY / ACCESSWIRE / October 15, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of CoLucid Pharmaceuticals (NasdaqGM: CLCD), a clinical-stage biotechnology company that completed an initial public offering in May 2015. The Company is developing lasmiditan, a novel acute therapy for migraine episodes with a differentiated mechanism of action from triptans, the current standard-of-care.

Triptans are contraindicated for individuals with cardiovascular disease due to vasoconstrictive effects, leaving these patients with no suitable treatment option. CoLucid is positioning lasmiditan as a first-line therapy for individuals with cardiovascular risk factors or stable disease or as a second-line therapy for those who do not respond to triptans. The Company has successfully completed a Phase IIb trial for the acute treatment of migraine in 391 patients demonstrating that oral lasmiditan can provide meaningful migraine relief. The Company is currently conducting the first of two pivotal Phase III trials which will be used to support a New Drug Application (NDA) filing. Data from this trial, which will potentially provide an important indication of the drug’s efficacy, is expected in the third quarter of 2016.

In a 29 page Initiation Report LifeSci Capital explains the unmet medical need for acute migraine therapies, lasmiditan’s unique mechanism of action which provides migraine relief in the absence of any vasoconstrictive effects, and the large market opportunity for an approved therapeutic.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on CoLucid as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital

ReleaseID: 432741